EP4 agonist
Provided is a compound represented by the formula (1): wherein R 1 and R 2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R 3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI 2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
1. A method of treating a disease whose symptoms can be mitigated by a selective EP4 agonist action in a subject, comprising administrating to the subject an effective amount of a compound represented by the formula (1):
wherein R 1 and R 2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1 to 3, and R 3 is a hydrogen atom, an alkyl group having a carbon number of 1 to 4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the disease is an immune disease, a cardiovascular disease, a cardiac disease, a skin disease, calvities, alopecia, cervical ripening failure, or a hearing disorder, thereby treating the disease in the subject.
2. The method of claim 1 , wherein R 1 is a methyl group, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein R 3 is a methyl group, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein R 2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein R 1 is a methyl group, and R 2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein R 3 is an m-methyl group, or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein R 1 is a methyl group, R 2 is a hydrogen atom, and R 3 is a methyl group, or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein R 1 is a hydrogen atom, R 2 is a methyl group, and R 3 is a methyl group, or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , which is 4-[(Z)-(1S,5R,6R,7R)-6-[(1E,3R,4RS)-3-hydroxy-4-(m-tolyl)-1-pentenyl]-7-hydroxy-2-oxa-4,4-difluoro-bicyclo[3,3.0]octan-3-ylidene]-1-(tetrazol-5-yl)butane, 4-[(Z)-(1S,5R,6R,7R)-6-[(1E,3R,4R)-3-hydroxy-4-(m-tolyl)-1-pentenyl]-7-hydroxy-2-oxa-4,4-difluoro-bicycl[3.3.0]octan-3-ylidene]-1-(tetrazol-5-yl)butane, 4-[(Z)-1S,5R,6R,7R)-6-[(1E,3R,4S)-3-hydroxy-4-(m-tolyl)-1-pentenyl]-7-hydroxy-2-oxa-4,4-difluoro-bicyclo[3.3.0]octan-3-ylidene]-1-(tetrazol-5-yl)butane, or a pharmaceutically acceptable salt thereof.
10. The method according to claim 1 , wherein the immune disease is Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, post-transplantation rejection, arthritis, systemic inflammation response syndrome, sepsis, hemophagocytic syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, hypercytokinemia at dialysis, multiple organ failure, shock or psoriasis.
11. The method according to claim 1 , wherein the cardiovascular disease or cardiac disease is arteriosclerosis, angina pectoris, myocardial infarction, brain disorder caused by cerebral hemorrhage, brain disorder caused by cerebral infarction, brain disorder caused by subarachnoid hemorrhage, pulmonary arterial hypertension, peripheral arterial obstruction or a symptom attributed to peripheral circulatory disturbance.
12. The method according to claim 1 , wherein the skin disease is pressure ulcer or wound.